Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis

Circulation

Volumn 101, Issue 22, 2000, Pages 2658-2661

  Gonze, Mark D ^a   Salartash, Khashayar ^a   Sternbergh III, W Charles ^a   Baughman, Robert A ^b   Leone Bay, Andrea ^a   Money, Samuel R ^a,c  

^a OCHSNER MEDICAL CENTER   (United States)

^b Emisphere Technologies   (United States)

^c Department of Surgery ^*  (United States)

Author keywords

Heparin; Thrombosis; Veins

Indexed keywords

ANTICOAGULANT AGENT; DRUG CARRIER; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OCTANOIC ACID DERIVATIVE; SODIUM N [8[2 HYDROXYBENZOYL]AMINO]CAPRYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EXPERIMENTAL MODEL; HEMATOLOGICAL PARAMETERS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOSIS; TREATMENT OUTCOME;

EID: 0034612268     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.22.2658     Document Type: Article

References (17)

1. Linhardt RJ, Loganathan D. Heparin, heparinoids, oligosaccharides. In: Gebelein CG, ed. Biomimetic Polymers. New York, NY: Plenum Press; 1990:135-173.
2. Gonze MD, Manord JD, Leone-Bay A, et al. Orally administered heparin for preventing deep venous thrombosis. Am J Surg. 1998;176:176-178.
3. Blake A, Ashwin T, Jacques LB. An assay for the antithrombotic activity of anticoagulants. J Clin Pathol. 1959;12:118-122.
4. Landefield CS, Hanus P. Economic burden of venous thromboembolism. In: Goldhaber SZ, ed. Prevention of Venous Thromboembolism. New York, NY: Marcel Dekker; 1993:69-85.
5. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis. 1994;36:417-422.
6. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
7. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1995;108(suppl):335S-351S.
8. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
9. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
10. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med. 1996;334:677-681.
11. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
12. Hiebert LM, Wice SM, McDuffie NM, et al. The heparin target organ: the endothelium: studies in a rat model. Q J Med. 1993;86:341-348.
13. Fischer A, Astrup T. Administration of heparin by mouth. Proc Soc Exp Biol Med. 1939;42:81-88.
14. Del Pozzo A, Acquasaliente M, Geron MR. New heparin complexes active by intestinal absorption, I: multiple ion pairs with basic organic compounds. Thromb Res. 1989;56:119-124.
15. Hardman JB, Limbird LE. Anticoagulants, thrombolytics, and antiplatelet drugs. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York, NY: Macmillan; 1996:1344-1346.
16. Hirsh J. Optimal therapeutic ranges for unfractionated heparin and low molecular weight heparins. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorder. Philadelphia, Pa: Saunders; 1992:147-160.
17. Baughman RA, Kapoor SC, Agarwal RK, et al. Oral delivery of anticoagulant doses of heparin: a randomized, double-blind, controlled study in humans. Circulation. 1998;98:1610-1615.